ArticleScientific reports2026
Clonidine protects rat hippocampal and cortical neurons from oxygen-glucose deprivation and reoxygenation-induced injury through HCN Channels.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Our prior research demonstrated that the neuroprotective effects of clonidine can be reversed by yohimbine, an α2-adrenergic receptor antagonist. Additionally, clonidine has been shown to alleviate anxiety-like behavior in rats after bilateral common carotid artery occlusion by reducing the expression of proteins associated with hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels. However, the specific mechanisms by which clonidine inhibits HCN channels remain unclear. This study was designed to explore the protective effects of clonidine on neurons subjected to oxygen-glucose deprivation (OGD) injury and elucidate the underlying molecular mechanisms via HCN channels. The protective effects of clonidine on OGD-exposed neurons were confirmed by assessing the neuronal viability using a cell counting kit-8 (CCK-8) assay and by measuring the lactate dehydrogenase (LDH) release. Moreover, we identified the signaling pathways most relevant to clonidine’s action. PCR was performed to assess the PKA, AKT, HCN1, and HCN2 gene expressions, and a western blot assay was used to evaluate the related protein expressions of the AC–cAMP–PKA cascade, the PI3K/Akt pathway, and the HCN channels. Clonidine and ZD7288 individually enhanced neuronal viability under OGD, demonstrating neuroprotective effects, with their combination yielding greater benefit. Clonidine upregulated α2A-AR and Nischarin protein levels. Its protection was attenuated by yohimbine (an α2-AR antagonist) and, to a lesser extent, by efaroxan (an I1R antagonist). KT5720, an AC–cAMP–PKA pathway inhibitor, synergized with clonidine and suppressed OGD-induced increases in HCN1 and HCN2 expression. Conversely, LY294002, a PI3K/Akt inhibitor, counteracted clonidine’s protection and further enhanced HCN1/HCN2 expression. These findings indicate that clonidine protects against OGD-induced injury mainly via α2-AR and partially through I1R, potentially by modulating HCN channels via the AC–cAMP–PKA and PI3K/Akt pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.